MOR News and Press, MorphoSys AG

2024-06-20 04:02:15 ET More on MorphoSys, Novartis, etc. Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript) Novartis: Buy This Blue-Chip Dividend Stock On Sale Now MorphoSys: Hold Rating Until The Novartis Deal Closes Novartis, Roche facing...

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...

2024-06-16 08:12:27 ET Summary In recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completion of its acquisition of Escient Pharmaceuticals for $...

2024-06-15 22:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-06 09:07:10 ET Summary AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC. Bristol...

2024-05-16 15:08:23 ET More on MorphoSys MorphoSys: Hold Rating Until The Novartis Deal Closes MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript MorphoSys reports Q1 results New safety risk for MorphoSys drug could complicate Novartis deal - STAT (update) ...

2024-04-30 20:36:07 ET Summary MorphoSys acquired by Novartis for EUR 2.7 billion, showcasing a significant premium over pre-announcement share price. The deal is expected to go through smoothly based on regulatory approvals received and successful precedents of similar M&A tr...

2024-04-30 06:15:05 ET Oddo BHF analyst issues NEUTRAL recommendation for MOR on April 30, 2024 04:35AM ET. MOR was trading at $17.36 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy, 1 - Hold, 1 -...

– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion – Received all mandatory antitrust approvals for the proposed acquisition by Novartis – S...